Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC — Stella

Recruiting

Back to Oral Squamous Cell Carcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality

Key details

Phase

Safety & dosing / Large-scale testing

Sponsor

Shanghai Jiao Tong University School of Medicine

Enrollment target

~80 participants

Started

October 2021

Primary completion

September 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated November 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov